Skip to content

Author

Xiaobo Zeng

We have 2 of 2 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Jul 2026

Dual-targeting CD73/PD-L1 bifunctional inhibitor: a promising cancer immunotherapy strategy

CP-1 exhibits balanced, dual-nanomolar inhibitory activity against PD-L1 and CD73 and displays potent immunomodulatory effects at the cellular level and serves as a promising lead candidate for developing novel bifunctional agents to advance tumor immunotherapy.

Jing-Jing Du, Sen Wu, Shiyun Cheng et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.